Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.
Also called NCT02220920
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 146 participants
- Sponsor
- Registry
-
NCT02220920
-
- Other papers using this trial's data
- Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02220920. Randomized; triple masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2015-07 (actual). Results posted on 2016-12-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Canagliflozin (TA-7284)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Insulin
- Lead sponsor
- Tanabe Pharma Corporation
Record details
- Record id
cardio:ct-nct02220920- Content hash
4fdacf0d5ebe63dd086078b6ec13c595f51a86631ae00e760dcf7c7836503d5e